Silk Road unveils results from ROADSTER-2 study of transcarotid stent
Category: #health  By Paroma Bhattacharya  Date: 2019-06-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Silk Road unveils results from ROADSTER-2 study of transcarotid stent

Silk Road Medical, Inc., a medical device company focused on reducing the risk of stroke and its harmful impact, has recently announced positive final results for its ROADSTER-2 post-marketing study which evaluated the real world use of the company’s ENROUTE® Transcarotid Neuroprotection & Stent System in TransCarotid Artery Revascularization (TCAR) procedures.

At the Society for Vascular Surgery’s Vascular Annual Meeting 2019, Chief of Endovascular Therapy and Vascular Surgery at University Hospitals Case Medical Center and National Co-Principal investigator of ROADSTER-2, Dr. Vikram Kashyap, stated that the study had represented compelling patient outcomes.

Dr. Kashyap informed that the study demonstrated combined stroke and death and low stroke rates of 0.8% and 0.6%, in 632 high surgical risk patients registered across 42 sites and out of which 70% of patients registered in the study were from physicians new to TCAR.

Apparently, the results of ROADSTER-2 would continue to represent the effectiveness, safety and clinical benefits of TCAR, specifically given that most of the TCAR procedures were conducted by a wide group of physicians with no former TCAR experience, Dr. Kashyap said.

Sources familiar with the matter mentioned that the study results represent the short learning curve of the TCAR procedure and its notable reproducibility and consistency. The company believes that it will further encourage physicians to widely adopt the TCAR procedure.

Reportedly designed as a follow-on study to the essential ROADSTER trial, ROADSTER-2 is a multi-center, prospective study which is designed to evaluate the real-world usage of the ENROUTE Transcarotid Stent when it is used with the ENROUTE Transcarotid Neuroprotection System by several physicians of different experience with the TCAR procedure.

The study seemingly met its primary endpoint of procedural success, demonstrated as acute device and technical success in the absence of stroke, myocardial infarction (MI) or death at 30 days, at 97.9%, sources added.

 

Source Credit: https://investors.silkroadmed.com/news-releases/news-release-details/roadster-2-demonstrates-compelling-patient-outcomes-strong



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...